The researchers’ uMRD analysis was from the phase 2 trial that included 43 patients with BCG-unresponsive (relapsed/refractory) NMIBC treated with the novel intravesical therapy Adstiladrin. To enroll ...

PARSIPPANY, N.J., February 12, 2025--First real-world outcomes data for ADSTILADRIN® (nadofaragene firadenovec-vncg) to be presented at 2025 ASCO Genitourinary Cancers Symposium ...

Ferring activates first sites in a three-arm study of ADSTILADRIN as a monotherapy or in combination with chemotherapy or an immune checkpoint inhibitor in high-risk Bacillus Calmette-Guérin (BCG ...

Contacts More information is available at the following: Health Care Providers: If you are interested in becoming part of the ADSTILADRIN Early Experience Program, please sign up for updates at ...

Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals. DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only.

ADSTILADRIN has been studied in a clinical trial program that includes 157 patients with high-risk, BCG-unresponsive NMIBC who had been treated with adequate BCG previously and did not see benefit ...

Adstiladrin ® (nadofaragene firadenovec-vncg) is now fully available for the treatment of adults with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer ...

PARSIPPANY, N.J., April 24, 2025 -- (BUSINESS WIRE)--Ferring Pharmaceuticals announced today the U.S. Food and Drug Administration (FDA) approved a state-of-the-art drug product manufacturing hub in ...

Independent experience at three Mayo Clinic sites and real-world outcomes data with ADSTILADRIN in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...